- Laquinimod ― Phase III trials proceeding as planned, results from Phase II extension study published in scientific journal
- TASQ ― preparations ongoing for start of Phase III in first half of 2011
- ANYARA ― ongoing phase III trial expected to be concluded in first half of 2012
- 57-57 ― exploratory SLE clinical trial completed
- ISI ― project continuing according to plan
- RhuDex(TM) ― preparations for continued clinical development in progress
- Net sales of SEK 8.5 M (7.7)
- Operating loss of SEK 149.7 M (loss: 164.6)
- Loss after tax SEK 156.8 M (loss: 165.1)
- Loss per share for the period amounted to SEK 2.40 (loss: 2.90)
For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95
Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54
Hans Kolam
CFO
Tel: +46 (0)46-19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
